a Objective: To assess if the reduction in HIV-1 RNA in CD4 þ T cells is correlated with the persistence of immune activation following early antiretroviral therapy (ART).
Design: Clinical trial (NCT01285050).
Methods: Next-generation sequencing was used to study total RNA from activated CD4 þ T cells (CD38 and human leukocyte antigen -antigen D related (HLA-DR) expressing) collected from 19 treatment-naïve HIV-1/hepatitis C virus-infected patients before and early after ART initiation (!12 weeks after plasma HIV-1 RNA <50 copies/ml). To validate comparisons, pre and post-ART measures were adjusted for input RNA and overall read number. ). The decrease in HIV-1 reads in activated CD4
þ T cells was associated with the change in plasma HIV-1 RNA levels (r ¼ 0.77, P ¼ 2 Â 10 Introduction Antiretroviral therapy (ART) durably suppresses HIV-1, prevents progression to AIDS, and reduces mortality. However, even with ART HIV-1 infected adults remain at higher risk of cardiovascular disease, dyslipidemia, insulin resistance, liver, kidney and bone dysfunction, neurocognitive disorders, accelerated biological aging, and cancer [1, 2] . Although the precise pathophysiology of many of these disorders is poorly understood, a syndrome of chronic immune activation and inflammation is a common feature [3, 4] .
With initial HIV-1 infection, there is activation of innate and adaptive immunity that alters T-cell homeostasis as characterized by elevated human leukocyte antigen -antigen D related (HLA-DR), CD38, CD57, programmed cell death protein-1 and cytotoxic T-lymphocyte-associated protein (CTLA)-4 expression, and lower expression of CD28 [5] [6] [7] [8] [9] [10] [11] [12] [13] , as well as enhanced expression of many cytokines and chemokines including interferon (IFN) a, IFNg, tumour necrosis factor alpha (TNFa), interleukin (IL)-6, IL-8, and C-X-C motif ligand10 [14, 15] . Cellular activation of CD4 þ and CD8 þ T cells, defined by coexpression of the surface markers HLA-DR and CD38, has been most closely associated with disease pathogenesis [7, 8, 11, 16] . Even when HIV-1 viremia has been suppressed for years, the proportion of HLA-DRþ/CD38 þ T cells remains higher than in uninfected persons and is correlated with failure to restore circulating CD4 þ T cells and development of disease [2, 7, 17] .
A dominant mechanism for HIV-1 persistence is the generation of a 'silent' provirus in resting memory CD4 þ T cells that is unaffected by ART or host-immune responses [18] [19] [20] [21] [22] . Some noninduced proviruses are capable of replicating if ART is stopped [23, 24] . However, the functional consequences of persistent intracellular viral RNAs remain unclear. It is plausible that cell-associated viral RNA, even in the absence of virion production and infection of new cells, could sustain host innate immune responses and contribute to immune activation [25, 26] . Here we show that, even after more than 12 weeks of undetectable viremia following ART, HIV-1 RNA persists in activated CD4 þ T cells, and that cell-associated HIV-1 RNA is associated with the reduction in CD4 þ T-cell activation and expression of host IFN-stimulated genes (ISG).
Methods
Human study participants Persons with HIV-1/hepatitis C virus (HCV) coinfection were enrolled in a prospective study designed to test the effect of HIV-1 control on HCV that is extensively described elsewhere [27] . Persons with untreated chronic HIV-1 and HCV infections were recruited from the Johns Hopkins HIV-1 Clinic, the Baltimore City Sexually Transmitted Diseases Clinic, and other area clinics. HIV-1 infection was established by detection of HIV-1 antibodies and an HIV-1 RNA level more than 400 copies/ml; chronic HCV infection was determined by detection of HCV antibodies and HCV RNA more than 100 000 IU/ml for more than 6 months. Study participants had received fewer than 24 months of ART over their entire lives and none within 6 months of enrollment. Study participants also were excluded if hepatitis B surface antigen was detected in plasma; they were pregnant; there was a history of severe depression or any uncontrolled disease; platelet count was less than 50 000/ml; or if there was a contraindication to use of raltegravir, tenofovir disoproxil fumarate, or emtricitabine. Because therapy was judged too urgent to wait for study procedures as per current treatment guidelines for HIV-1 and HCV, persons at screening whose CD4 þ T-cell counts were less than 200/ml or who had cirrhosis were excluded. A total of 32 patients were screened to identify 20 study participants, and 19 completed the study. All study participants gave written informed consent to the protocol as approved by the Johns Hopkins University School of Medicine Institutional Review Board.
All study participants had received a single injection of peg-IFNa 2b 2 weeks prior to ART initiation to study the response of HIV-1 and HCV to IFN prior to ART. Two weeks following IFN administration, after plasma HIV-1 RNA levels normalized, ART consisting of raltegravir, tenofovir disoproxil fumarate, and emtricitabine was initiated. Participants were followed until their plasma HIV-1 RNA levels had been undetectable for at least 12 weeks after ART initiation. Peripheral blood mononuclear cells (PBMCs) were collected prior to ART initiation and at regular intervals for at least 12 weeks after ART initiation. The first specimen collected for sequencing (pretreatment) was acquired before the first peg-IFN injection and the second specimen (ART) was collected after at least 12 weeks of continuous suppressed viremia, HIV-1 RNA less than 50 copies/ml, more than 4 months later.
HIV-1 RNA quantitative PCR testing was performed using the Abbott RealTime HIV-1 Assay (No. 02631-090). CD4 þ T-cell count was measured by flow cytometry of whole blood that was delivered to the Johns Hopkins Hospital clinical laboratory.
Isolation of activated T cells
PBMCs were separated from whole blood and frozen. Freshly thawed cells were washed and incubated with CD3-fluorescein isothiocyanate (Biolegend, San Diego, California, USA), CD4-phycoerythrin-C g tandem conjugate (Biolegend), CD8-allophycocyanin (BD Biosciences, Franklin Lakes, New Jersey, USA), HLA-DRphycoerythrin (Biolegend), and CD38-Brilliant Violet 421 (Biolegend) for 40 min at 48C per the manufacturer's recommendation. Immediately before sorting, plasma membrane compromised cells were labeled with propidium iodide (Sigma, St Louis, Missouri, USA). Fluorescence-activated cell sorting was performed on a MoFlo Legacy Sorter (Beckman-Coulter, Brea, California, USA) at the Johns Hopkins School of Public Health Flow Cytometry Core Facility. Gates were set using fluorescence minus one and isotype control. Because flow and sorting had to be performed over several sessions, the gates were set each session using a reference participant's PBMCs (selected based on availability of cells). The population of interest was sorted directly into at least four volumes of Quick-RNA MicroPrep lysis buffer (Zymo Research, Irvine, California, USA) per the manufacturer's recommendation. Sorting was stopped when the number of sorted cells reached 125 000 cells, although many samples did not reach this number. Flow cytometry analysis on two randomly selected postsort samples revealed more than 95% purity. Sorted samples were vortexed, incubated for 10 min at room temperature, vortexed again, and frozen at À808C until isolation.
RNA preparation and sequencing
Isolation was performed using the Quick-RNA MicroPrep kit (Zymo Research) according the manufacturer's protocol without the on-column DNAase treatment. The eluate was treated with DNase-I (Qiagen, Hilden, Germany) according to the manufacturer's protocol, then purified and concentrated using the RNA Clean-up and Concentrator kit (Zymo Research) according the manufacturer. The high-sensitivity assay for RNA or DNA was performed on RNA isolations and cDNA libraries respectively using a 2100 Biolanalyzer (Agilent, Santa Clara, California, USA).
cDNA libraries were produced using the Ovation Single-cell RNAseq kit (NuGEN) according to the manufacturer's specifications. Briefly, reverse transcription was carried out using a random hexamer to oligo deoxythymine ratio of 50 : 1 and unique barcodes for each individual's samples were ligated to $250 bp enzymatically fragmented molecules. All samples were linearly amplified with 19 cycles of PCR using primer annealing sites contained within the adapters. All sequencing was performed on a HiSeq2500 (Illumina, San Diego, California, USA) at the Johns Hopkins Genetics Research Core Facility. All sequencing data are deposited in the National Center for Biotechnology Information Sequence Read Archive (accession number SRP068424).
Human sequence mapping and differential expression calculation Reads were aligned to the human genome (hg)19 reference genome and annotated transcripts with RSEM (version 1.2.9) [28] . Differential expression of genes and isoforms was calculated using EBseq (version 1.11.0) [29] , an empirical Bayes hierarchical model for expression analysis of RNAseq data. The human sequence mapping and differential expression calculation was performed at the Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center Next Generation Sequencing core.
HIV-1 genome sequence mapping
The reads were first quality trimmed using the Phred algorithm with seqtk trimfq (version 1.0, error rate threshold 0.05, https://github.com/lh3/seqtk), and sequences shorter than 31 bps, after quality trimming, were discarded. The remaining reads were mapped to the human genome (build hg19) with bowtie2 (version 2.2.6) [30] using local alignment as a filter. All reads that did not align to the human genome were then mapped against a pool of 2153 validated HIV-1 genomes, and the HIV-1 reference genome, that were listed in the National Center for Biotechnology Information Viral Genome Resource [31] as of 18 July 2016 (Table S1 , http://links.lww.com/ QAD/B75). The reads were extracted using samtools (version 1.3) [32] and aligned to an index compiled from the HIV genomes with bowtie2. The resulting alignments were cleaned of PCR duplicates using Picard MarkDuplicates (version 1.119, http://broadinstitute. github.io/picard). Percentage identity and alignment length for the HIV reads were calculated from SAM tags, and only reads with at least 80% identity over the aligned sequence, and alignment length of 31 bps, were kept. The genome coverage was calculated with samtools mpileup. The data was loaded in R version 3.3.1 [33] and visualized using ggplot2 version 2.20 [34] .
Statistical analyses
Comparison values, including postcorrection fold change, postcorrection probability of differential expression, and postcorrection probability of equal expression (PPEE) values, were further analyzed using 'stats' in R version 3.1.2. Measurements for which neither the postcorrection probability of differential expression nor PPEE were at least 0.95 were discarded as being of low confidence. In the determination of significance of a gene's change across the cohort after ART, all fold-change calculations with PPEE at least 0.95 were set to 0, reflecting the certainty of the PPEE. If there were remaining measurements for a gene in more than 10 of the individuals, a two-sided one-sample t test was performed on log 2 transformed fold-change values. The resulting P values were adjusted for multiple comparisons using the Benjamani-Hochberg method. Spearman rank correlations were performed between fold changes of the observed ISGs and intracellular HIV-1 
Results
We collected samples from nineteen patients with HIV-1 and chronic HCV coinfection who completed the study ( Table 1) . The median (range) plasma HIV-1 RNA and CD4 þ T-cell counts at baseline were 4.27 log 10 copies/ml (2.91-5.44 log copies/ml) and 376 cells/ml (203-759 cells/ml), respectively. ART resulted in suppressed viremia in all participants and a median (IQR) increase in CD4 þ T-cell count of 90 cells/ml (28-151 cells/ml) [27] . Populations of activated CD4 þ and CD8 þ cells from total CD3 þ T cells in PBMCs of patients before and after ART are shown in Fig. 1a [35] [36] [37] . In addition, CD4 þ and CD8 þ T-cell activation were closely associated with each other (Figs. 1d and e ).
PBMCs were sorted before treatment was initiated and at least 12 weeks after plasma HIV-1 RNA was suppressed to isolate purified populations of activated CD4 þ T cells, defined as CD3
þ . cDNA libraries were prepared from purified cells and a median (IQR) of 90.5 (85.4-107.6) million and 86.2 (83.5-99.6) million 100 bp paired-end sequences were obtained before and following ART initiation, respectively (Table  S2, multiple comparisons, no single gene was consistently differentially expressed pre vs. post-ART across the 19 individuals in the cohort. We considered ISGs as a separate group of genes whose expression is triggered in response to viral infections (Table S3 , http://links.lww. com/QAD/B77). Of the 18 individuals in the cohort for whom cells were available, 17 had a significant change in ISGs (P value range ¼ 3 Â 10 À40 to 0.006). Fifteen of the individuals had a significant decrease in ISG expression, whereas only two had an increase in ISG expression (Fig. 2) . When the median fold changes across the cohort were considered, ISGs were decreased compared with all other genes. Of the 96 ISGs examined, 84.4% were downregulated post-ART (P < 2 Â 10
À16
, for comparison with fold change of non-ISGs) and the median (IQR) magnitude of the changes among ISGs was À0.244 log 2 fold (À0.438 to À0.0396; Fig. S2 , http://links.lww.com/ QAD/B74).
We next quantified HIV-1 RNA in activated CD4 þ T cells by aligning RNA sequences to a reference panel of 2153 HIV-1 genome sequences (Fig. 3a) . Cell-associated HIV-1 RNA was detected both before and after ART initiation, but was less abundant during ART. A median (IQR) of 959 (252-1614) reads/10 7 reads and 72 (55-152) reads/10 7 reads mapped to HIV-1 before and after ART initiation, respectively ( Fig. 3b ; P ¼ 8 Â 10 À5 ). In addition, pre-ART cell-associated HIV-1 RNAs were strongly associated with contemporaneous plasma HIV-1 RNA levels (R ¼ 0.79, P ¼ 5 Â 10 À5 ), and the decrease in cell-associated HIV-1 RNAs was associated with the suppression of plasma viremia (R ¼ 0.77, P ¼ 2 Â 10 À4 ; Fig. 3c ).
At baseline, cell-associated HIV-1 RNA and global CD4 þ T-cell activation were not correlated (Fig. 4a) . However, the decrease in the proportion of CD3
was strongly associated with the decrease in intracellular HIV-1 RNA in the same activated cells (R ¼ 0.70, P ¼ 0.002; Fig. 4b ). In contrast, the change in proportion of CD3
þ /HLA-DR þ T cells after ART initiation was weakly associated with the change in plasma HIV-1 RNA levels (R ¼ .43 P ¼.076; Fig. 4c ).
Discussion
Despite the success of ART in improving clinical outcomes in patients with HIV-1, increasing non-AIDS morbidity and mortality have prompted efforts to understand the association between ART-suppressed virus persistence and host immunity. We found that the change in plasma and cell-associated HIV-1 RNA abundance following ART were strongly correlated, and that the decrease in cell-associated HIV-1 RNA was strongly associated with the reduction in CD38 þ and HLA-DR þ CD4 þ T cells. In addition, ART use was strongly associated with diminished expression of a panel of ISGs in activated CD4 þ T cells. These findings are consistent with previous reports of decreases in cellassociated HIV-1 RNA in unsorted PBMCs [11] ; however, in the present manuscript we measured cellassociated HIV-1 RNA strictly in activated CD4 þ T cells, and linked this finding with the proportion of activated CD4 þ T cells and ISG expression in those cells. 
ISGs in CD4 þ T cells is one of the hallmarks of immune activation [38] . We found that the levels of 96 established ISGs in activated CD4 þ T cells (Table S3 , http:// links.lww.com/QAD/B77) were significantly reduced en masse in patients on ART when compared with all evaluated genes (Fig. 2) .
The finding of a correlation between the reduction in intracellular HIV-1 RNA and activated CD4 þ T-cell change on ART is interesting in light of emerging data that suggest the virus itself may contribute to immune activation even in persons taking ART. Although production of new, replication-competent virus appears to be aborted by ART, HIV-1 RNA has been previously identified in CD4 þ T cells in patients taking ART [39] . Low copy numbers of HIV-1 RNA, as well as an excess of short abortive transcripts have been identified in latently infected resting memory CD4 þ T cells in patients on therapy [24, 39] . Although the functional consequence of these nonproductive or dead RNAs remains unclear, our data could support that persistent inactive viral RNAs in activated cells may lead to innate immune signaling. However, because plasma HIV-1 changes were strongly correlated with cell-associated HIV-1 RNA changes, an alternative explanation is that those with the largest plasma HIV-1 reductions had the greatest restoration in CD4 þ T cells not expressing HLA-DR or CD38. In light of findings by Murray et al. [40] that ART leads to a biphasic decrease in CD4
þ T cells with a corresponding decline in total proviral DNA, we speculate that our findings may be related to the slow kinetics of turnover of the HIV-1 reservoir.
There were several challenges in our study. Because we employed a sorting strategy of activated CD4 þ T cells, we were limited in the total amount of RNA that was available for individually targeted assays. Consequently, we did not fully characterize the HIV-1 RNAs or establish if they could propagate infection. Fortunately, on ART, few/no of the RNAs would have been expected to propagate infection, and those limitations should not have affected our within-person comparisons. Another potential challenge was in our choice to study activated CD4 þ T cells exclusively. As activation itself promotes HIV-1 transcription, an expected but overgeneralized result would be to find less intracellular HIV-1 RNA during ART. However, although this would be true in a study of global CD4 þ T cells, we specifically studied activated CD4 þ T cells and adjusted for total transcription in those same cells. Another limitation is that we provide no mechanism explaining how CD8 þ T cells would become activated, even though that cell type is strongly associated with the clinical immune activation outcomes. We note, however, that CD4 þ and CD8 þ T-cell activation were closely related ( Fig. 1d and e) . Moreover, several studies have reported that CD4 þ T-cell activation also is associated with clinical outcomes [11, 16] . We also note that all participants in the present study were chronically co-infected with HCV, as is common among HIV-1 infected people who inject drugs in Baltimore, Maryland, USA [41] . It is possible that other HIV-1 infected populations, including those without chronic HCV infection, might respond differently. However, our findings of a decrease in CD4 þ and CD8 þ T-cell activation are consistent with previous studies in which HCV status was not presented [42] .
All participants were treated with a single injection of pegylated IFNa 2b after acquisition of the 'pretreatment' samples and at least 12 weeks prior to the 'ART' specimen collection. Although this could have led to an IFN refractory period, it would be unexpected for such a phenomenon to be present more than 4 months later. Indeed, ISG expression was observed to decrease to baseline values in rhesus macaques after 4 weeks despite weekly administration of exogenous pegylated IFNa [43] .
We investigated the impact of 3 months of ART on HIV-1 cell-associated RNA activated CD4 þ T cells. The reduction in activated CD4
þ T cells was associated with the reduction in HIV-1 cell-associated RNAs and ISG expression. These findings provide new insights into the early effects of ART on a critical CD4 þ T-cell compartment. 
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